Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 507,654
  • Shares Outstanding, K 85,320
  • Annual Sales, $ 420 K
  • Annual Income, $ -70,790 K
  • 36-Month Beta 2.13
  • Price/Sales 1,170.14
  • Price/Cash Flow N/A
  • Price/Book 3.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.19
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.52 +6.16%
on 09/18/18
6.68 -12.28%
on 09/28/18
+0.36 (+6.55%)
since 09/17/18
3-Month
5.22 +12.26%
on 08/07/18
6.68 -12.28%
on 09/28/18
+0.19 (+3.35%)
since 07/17/18
52-Week
4.41 +32.88%
on 12/19/17
6.77 -13.44%
on 10/18/17
-0.84 (-12.54%)
since 10/17/17

Most Recent Stories

More News
New Research: Key Drivers of Growth for Haverty Furniture Companies, BLACKLINE INC, MagnaChip Semiconductor, Kinross Gold, Aurinia Pharmaceuticals, and NEXEO SOLUTIONS -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Haverty Furniture Companies,...

NXEO : 11.60 (-0.09%)
AUPH : 5.86 (-1.51%)
KGC : 2.86 (-1.04%)
HVT : 21.32 (-1.62%)
BL : 45.59 (+0.35%)
MX : 9.42 (+4.43%)
Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher

Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

AUPH : 5.86 (-1.51%)
PCRX : 48.04 (+2.19%)
Aurinia to Participate in Upcoming Investor Conferences

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences.

AUP.TO : 7.61 (-1.17%)
AUPH : 5.86 (-1.51%)
Investor Expectations to Drive Momentum within Natural Resource Partners LP, Insmed, MagnaChip Semiconductor, Changyou, Pain Therapeutics, and Aurinia Pharmaceuticals -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natural Resource Partners LP...

AUPH : 5.86 (-1.51%)
CYOU : 12.91 (-2.42%)
PTIE : 1.22 (+0.83%)
MX : 9.42 (+4.43%)
NRP : 33.55 (-0.36%)
INSM : 17.57 (+0.34%)
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -18.75% and 447.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

AUPH : 5.86 (-1.51%)
Aurinia Reports Second Quarter Financial Results and Operational Highlights

--Trials in FSGS and Dry Eye initiated

AUP.TO : 7.61 (-1.17%)
AUPH : 5.86 (-1.51%)
Today's Research Reports on Cipher Pharmaceuticals, Aurinia Pharmaceuticals, GeneNews and Neovasc

NEW YORK, NY / ACCESSWIRE / July 30, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register...

AUPH : 5.86 (-1.51%)
CPH.TO : 3.05 (+1.33%)
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial...

AUP.TO : 7.61 (-1.17%)
AUPH : 5.86 (-1.51%)
Aurinia Reports First Quarter Financial Results and Operational Highlights

--Trials in FSGS and Dry Eye expected to begin in June 2018

AUP.TO : 7.61 (-1.17%)
AUPH : 5.86 (-1.51%)
Aurinia Pharmaceuticals Recognizes World Lupus Day(TM)with Activities Focused on Raising Awareness of Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced its support for World Lupus Day(TM)...

AUP.TO : 7.61 (-1.17%)
AUPH : 5.86 (-1.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade AUPH with:

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

2nd Resistance Point 6.09
1st Resistance Point 5.98
Last Price 5.86
1st Support Level 5.76
2nd Support Level 5.65

See More

52-Week High 6.77
Fibonacci 61.8% 5.87
Last Price 5.86
Fibonacci 50% 5.59
Fibonacci 38.2% 5.31
52-Week Low 4.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar